Ranbaxy launches anti-malaria drug 'Synriam'
Drug major Ranbaxy Laboratories on Wednesday launched the first indigenously developed anti-malaria drug -- Synriam.
New Delhi: Drug major Ranbaxy Laboratories on Wednesday launched the first indigenously developed anti-malaria drug -- Synriam.
The Ranbaxy drug is a combination of two molecules, arterolanemaleate and piperaquine phosphate, and will need to be taken once a day by patients for three days.
"Today, India joins the elite club of the countries to have developed new drug indigenously for malaria on the occasion of World Malaria Day," Ranbaxy Laboratories CEO and MD Arun Sawhney told reporters here.
It will certainly become the preferred option in hands of doctors to fight malaria which every year claims more than half a million lives globally, he added.
In 2011, Ranbaxy received permission from the Indian Drug Regulator -- Drug Controller General of India (DCGI) -- to manufacture and market this drug in India.
Ranbaxy Laboratories shares closed down 1.80 per cent at Rs 515 on the BSE.